Here’s our weekly round-up of what illnesses are spreading the most in Metro Detroit communities, according to our local ...
AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
The first one was that several participants did not know the correct inhaler regimen that they were actively prescribed at ...
Among adults with COPD, those with vs. without cost-related nonadherence had worse symptom burden, health status and lung ...
BACKGROUND: Pulmonary rehabilitation has become a cornerstone in the management of patients with stable Chronic Obstructive Pulmonary Disease (COPD). Systematic reviews have shown large and important ...
Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...
The two studies — OBERON and TITANIA — evaluated the drug against placebo in adults with symptomatic COPD who had a history of at least two moderate or at least one severe COPD exacerbations (or ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...
Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...
Inflammation is a protective mechanism of the body but silent symptoms can lead to chronic inflammation and disease. Dr. Taz Bhatia, an integrative medicine physician and host of the “Hol+” podcast, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results